0A8S Stock Overview An advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Sintx Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sintx Technologies Historical stock prices Current Share Price US$3.66 52 Week High US$101.00 52 Week Low US$2.10 Beta 1.49 1 Month Change -33.01% 3 Month Change 9.76% 1 Year Change -95.06% 3 Year Change -99.97% 5 Year Change n/a Change since IPO -99.99%
Recent News & Updates
Sintx Technologies, Inc. Appoints Eric K. Olson to the Board of Directors Nov 30
Sintx Technologies, Inc.Appoints Gregg R. Honigblum as Chief Strategy Officer Nov 20
Insufficient new directors Nov 19
Sintx Technologies, Inc., Annual General Meeting, Dec 19, 2024 Nov 15
New major risk - Financial position Nov 14
Third quarter 2024 earnings released: US$6.96 loss per share (vs US$152 loss in 3Q 2023) Nov 14 See more updates
Sintx Technologies, Inc. Appoints Eric K. Olson to the Board of Directors Nov 30
Sintx Technologies, Inc.Appoints Gregg R. Honigblum as Chief Strategy Officer Nov 20
Insufficient new directors Nov 19
Sintx Technologies, Inc., Annual General Meeting, Dec 19, 2024 Nov 15
New major risk - Financial position Nov 14
Third quarter 2024 earnings released: US$6.96 loss per share (vs US$152 loss in 3Q 2023) Nov 14
Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T Oct 01 Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million. Sep 19
Second quarter 2024 earnings released: US$3.49 loss per share (vs US$122 loss in 2Q 2023) Aug 15 Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million. Jul 12
Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement Jun 14
Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market May 25
New major risk - Financial position May 15
First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023) May 15
Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Apr 13 Sintx Technologies, Inc. has filed a Follow-on Equity Offering. Mar 30
Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022) Mar 28 Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.
Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 23
Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022) Nov 17
Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023 Oct 26
SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 21
Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants Oct 12
New major risk - Revenue and earnings growth Aug 13
No longer forecast to breakeven Aug 12
Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022) Aug 10
First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022) May 17
Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021) Mar 31 Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million. Feb 09
Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million. Feb 08
Insufficient new directors Feb 01
Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 28
Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq Nov 24
Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16
Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022 Nov 05 Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million. Oct 14
Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio Oct 06
National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device Sep 30
Insufficient new directors Sep 26
Insufficient new directors Sep 07
Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings Aug 24
No longer forecast to breakeven Aug 16
Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021) Aug 14
Insufficient new directors Aug 10
Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million. Jul 07
Insufficient new directors May 27
Insufficient new directors Apr 27
No longer forecast to breakeven Apr 27
Insufficient new directors Apr 01
Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020) Mar 28
No longer forecast to breakeven Mar 28
Insufficient new directors Mar 18
SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics Feb 24
SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Jan 07
No longer forecast to breakeven Dec 10
Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020) Nov 13
Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY Jul 02
First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020) May 16
SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications May 12
SINTX Technologies Files Multiple New U.S. and International Patent Applications May 05 Shareholder Returns 0A8S GB Medical Equipment GB Market 7D 21.8% -2.3% -2.2% 1Y -95.1% -10.6% 2.4%
See full shareholder returns
Return vs Market: 0A8S underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A8S's price volatile compared to industry and market? 0A8S volatility 0A8S Average Weekly Movement 27.1% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A8S's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A8S's weekly volatility has decreased from 45% to 27% over the past year, but is still higher than 75% of UK stocks.
About the Company Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation.
Show more Sintx Technologies, Inc. Fundamentals Summary How do Sintx Technologies's earnings and revenue compare to its market cap? 0A8S fundamental statistics Market cap US$4.73m Earnings (TTM ) -US$11.65m Revenue (TTM ) US$3.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A8S income statement (TTM ) Revenue US$3.25m Cost of Revenue US$1.10m Gross Profit US$2.15m Other Expenses US$13.80m Earnings -US$11.65m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -8.68 Gross Margin 66.06% Net Profit Margin -358.79% Debt/Equity Ratio 2.4%
How did 0A8S perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 12:22 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sintx Technologies, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC David Turkaly JMP Securities Jeffrey Cohen Ladenburg Thalmann & Company
Show 3 more analysts 